What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance

International Journal of Antimicrobial Agents

Volumn 39, Issue 6, 2012, Pages 455-457

  Udy, Andrew A ^a,b   Roberts, Jason A ^a,b   De Waele, Jan J ^c   Paterson, David L ^a,b   Lipman, Jeffrey ^a,b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CEFTOBIPROLE; CILASTATIN PLUS IMIPENEM; DORIPENEM; LINEZOLID; PLACEBO; TIGECYCLINE;

ANTIBIOTIC RESISTANCE; CRITICALLY ILL PATIENT; DRUG CLEARANCE; DRUG EXPOSURE; DRUG PENETRATION; DRUG POTENTIATION; DRUG RESPONSE; DRUG TREATMENT FAILURE; EDITORIAL; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; KIDNEY CLEARANCE; LOADING DRUG DOSE; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; CARBAPENEMS; CEPHALOSPORINS; CRITICAL ILLNESS; CROSS INFECTION; HUMANS; KIDNEY; METABOLIC CLEARANCE RATE; PNEUMONIA; PNEUMONIA, VENTILATOR-ASSOCIATED; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84860465706     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2012.02.010     Document Type: Editorial

References (31)

1. W.A. Craig Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1998 1 10
2. P.G. Ambrose, S.M. Bhavnani, E.J. Ellis-Grosse, and G.L. Drusano Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap! Clin Infect Dis 51 Suppl. 1 2010 S103 S110
3. J.A. Roberts, P. Kruger, D.L. Paterson, and J. Lipman Antibiotic resistance - what's dosing got to do with it? Crit Care Med 36 2008 2433 2440
4. 'Dear Healthcare Professional' letter. Raritan, NJ: Janssen Pharmaceuticals Inc.; 3 January 2012. http://www.fda.gov/downloads/Drugs/ DrugSafety/UCM286277.pdf [accessed 12 February 2012].
5. M.H. Kollef Review of recent clinical trials of hospital-acquired pneumonia and ventilator-associated pneumonia: a perspective from academia Clin Infect Dis 51 Suppl. 1 2010 S29 S35
6. G. Noel, R. Strauss, A. Shah, and P. Bagchi Ceftobiprole versus ceftazidime combined with linezolid for treatment of patients with nosocomial pneumonia Program and abstracts of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 2008 Annual Meeting 25-28 October 2008, Washington, DC 2008 ASM Press Washington, DC [Abstract K-486]
7. A.T. Freire, V. Melnyk, M.J. Kim, O. Datsenko, O. Dzyublik, and F. Glumcher Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia Diagn Microbiol Infect Dis 68 2010 140 151
8. J. Lipman, A.A. Udy, and J.A. Roberts Do we understand the impact of altered physiology, consequent interventions and resultant clinical scenarios in the intensive care unit? The antibiotic story Anaesth Intensive Care 39 2011 999 1000
9. J.A. Roberts, and J. Lipman Pharmacokinetic issues for antibiotics in the critically ill patient Crit Care Med 37 2009 840 851
10. D. Di Giantomasso, C.N. May, and R. Bellomo Vital organ blood flow during hyperdynamic sepsis Chest 124 2003 1053 1059 (Pubitemid 37123329)
11. A.A. Udy, M.T. Putt, S. Shanmugathasan, J.A. Roberts, and J. Lipman Augmented renal clearance in the Intensive Care Unit: an illustrative case series Int J Antimicrob Agents 35 2010 606 608
12. A.A. Udy, J.A. Roberts, R.J. Boots, D.L. Paterson, and J. Lipman Augmented renal clearance: implications for antibacterial dosing in the critically ill Clin Pharmacokinet 49 2010 1 16
13. R.A. Cherry, S.R. Eachempati, L. Hydo, and P.S. Barie Accuracy of short-duration creatinine clearance determinations in predicting 24-hour creatinine clearance in critically ill and injured patients J Trauma 53 2002 267 271
14. J.M. Conil, B. Georges, O. Fourcade, T. Seguin, M. Lavit, and K. Samii Assessment of renal function in clinical practice at the bedside of burn patients Br J Clin Pharmacol 63 2007 583 594 (Pubitemid 46632572)
15. A. Udy, R. Boots, S. Senthuran, J. Stuart, R. Deans, and M. Lassig-Smith Augmented creatinine clearance in traumatic brain injury Anesth Analg 111 2010 1505 1510
16. W. Dunlop Serial changes in renal haemodynamics during normal human pregnancy Br J Obstet Gynaecol 88 1981 1 9 (Pubitemid 11184002)
17. R. Brown, R. Babcock, J. Talbert, J. Gruenberg, C. Czurak, and M. Campbell Renal function in critically ill postoperative patients: sequential assessment of creatinine osmolar and free water clearance Crit Care Med 8 1980 68 72
18. J. Lipman, S.C. Wallis, and R.J. Boots Cefepime versus cefpirome: the importance of creatinine clearance Anesth Analg 97 2003 1149 1154 (Pubitemid 37158705)
19. L.R. Shikuma, B.H. Ackerman, R.H. Weaver, L.D. Solem, R.G. Strate, and F.B. Cerra Effects of treatment and the metabolic response to injury on drug clearance: a prospective study with piperacillin Crit Care Med 18 1990 37 41 (Pubitemid 20039153)
20. R.N. Jones Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia Clin Infect Dis 51 Suppl. 1 2010 S81 S87
21. P.S. McKinnon, J.A. Paladino, and J.J. Schentag Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections Int J Antimicrob Agents 31 2008 345 351
22. A. Udy, J.A. Roberts, R.J. Boots, and J. Lipman You only find what you look for: the importance of high creatinine clearance in the critically ill Anaesth Intensive Care 37 2009 11 13
23. V.H. Tam, A.N. Schilling, S. Neshat, K. Poole, D.A. Melnick, and E.A. Coyle Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa Antimicrob Agents Chemother 49 2005 4920 4927 (Pubitemid 41778901)
24. A.Y. Peleg, B.A. Potoski, R. Rea, J. Adams, J. Sethi, and B. Capitano Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report J Antimicrob Chemother 59 2007 128 131 (Pubitemid 46017915)
25. J.A. Roberts, W.W. Hope, and J. Lipman Therapeutic drug monitoring of β-lactams for critically ill patients: unwarranted or essential? Int J Antimicrob Agents 35 2010 419 420
26. J.A. Roberts, R. Norris, D.L. Paterson, and J.H. Martin Therapeutic drug monitoring of antimicrobials Br J Clin Pharmacol 73 2012 27 36
27. J.A. Roberts, M. Ulldemolins, M.S. Roberts, B. McWhinney, J. Ungerer, and D.L. Paterson Therapeutic drug monitoring of β-lactams in critically ill patients: proof of concept Int J Antimicrob Agents 36 2010 332 339
28. J.P. Baptista, A.A. Udy, E. Sousa, J. Pimentel, L. Wang, and J.A. Roberts A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance Crit Care 15 2011 R139
29. A.A. Udy, J.M. Varghese, M. Altukroni, S. Briscoe, B. McWhinney, and J. Ungerer Sub-therapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations Chest 2011 10.1378/chest.11-1671 [Epub ahead of print]
30. J.A. Roberts, S. Webb, D. Paterson, K.M. Ho, and J. Lipman A systematic review on clinical benefits of continuous administration of β-lactam antibiotics Crit Care Med 37 2009 2071 2078
31. A.A. Mohd Hafiz, C.E. Staatz, C.M. Kirkpatrick, J. Lipman, and J.A. Roberts Continuous infusion vs. bolus dosing: implications for β-lactam antibiotics Minerva Anestesiol 78 2012 94 104